{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:03:34Z","timestamp":1782975814365,"version":"3.54.5"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013318","name":"Shanxi Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["202303021212317"],"award-info":[{"award-number":["202303021212317"]}],"id":[{"id":"10.13039\/501100013318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) has a poor prognosis, and identifying key driver genes and their molecular mechanisms is crucial for improving patient outcomes. While TOP2A is dysregulated in multiple cancers, its role and regulatory network in HCC remain incompletely understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Integrated bioinformatics analyses were performed using TCGA, ICGC, and GEO datasets. TOP2A expression and prognostic value were validated in 120 clinical samples via immunohistochemistry. Functional assays (including CCK-8, Transwell, and wound healing\n                      <jats:italic>in vitro<\/jats:italic>\n                      , as well as xenograft tumor models\n                      <jats:italic>in vivo<\/jats:italic>\n                      ) were conducted to assess phenotypic effects. Mechanisms were explored using ChIP-PCR, WB, and RT-qPCR. Prognostic models were developed using multivariate regression and evaluated using calibration curves, ROC, and DCA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TOP2A was significantly upregulated in HCC tissues, with an AUC of 0.935 for diagnosis, and high expression correlated with advanced stage and poor survival (p&amp;lt;0.05). A prognostic model incorporating TOP2A expression, TNM stage, and tumor grade showed robust predictive accuracy for 1-, 3-, and 5-year survival (AUCs: 0.77, 0.85, 0.75). Knockdown of TOP2A suppressed proliferation, migration, and invasion. Mechanistically, E2F6 transcriptionally activated TOP2A by binding to its promoter, while TOP2A promoted EMT by upregulating DKK1 and activating \u03b2-catenin signaling. High TOP2A expression predicted poor response to TACE, sorafenib, and immunotherapy. The candidate targeted agent, A-443654, alone or combined with anti-PD-L1, potently suppressed tumor growth\n                      <jats:italic>in vivo<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study delineates the E2F6-TOP2A-DKK1 axis as a key mechanism in HCC progression. TOP2A serves as a diagnostic and prognostic biomarker, and targeting this pathway offers a promising therapeutic strategy for HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1809952","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:36:04Z","timestamp":1782970564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression"],"prefix":"10.3389","volume":"17","author":[{"given":"Mindan","family":"Xing","sequence":"first","affiliation":[{"name":"The First Clinical Medical College of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]},{"name":"Department of Gastroenterology, First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Tianjin\u2019s Clinical Research Center for Cancer; Tianjin Lung Cancer Center, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]},{"name":"Department of Gastroenterology, First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Tianjin\u2019s Clinical Research Center for Cancer; Tianjin Lung Cancer Center, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengqi","family":"Liu","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Tianjin\u2019s Clinical Research Center for Cancer; Tianjin Lung Cancer Center, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Yu","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Tianjin\u2019s Clinical Research Center for Cancer; Tianjin Lung Cancer Center, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Tong","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Tianjin\u2019s Clinical Research Center for Cancer; Tianjin Lung Cancer Center, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Tianjin\u2019s Clinical Research Center for Cancer; Tianjin Lung Cancer Center, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[{"name":"Hepatobiliary Surgery, Zhuji Affiliated Hospital of Wenzhou Medical University","place":["Zhuji, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]},{"name":"Department of Gastroenterology, First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Luo","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Tianjin\u2019s Clinical Research Center for Cancer; Tianjin Lung Cancer Center, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00874-5","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"23","author":"Zhou","year":"2023","journal-title":"Clin Exp Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival: analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers during 2000\u20132014 from 322 population-based registries in 71 countries (CONCORD-3)","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet (Lond Engl)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-022-00452-3","article-title":"Human topoisomerases and their roles in genome stability and organization","volume":"23","author":"Pommier","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.564","article-title":"Alteration of topoisomerase II\u2013alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy","volume":"29","author":"Press","year":"2026","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.332","article-title":"Topoisomerase II\u03b1 in chromosome instability and personalized cancer therapy","volume":"34","author":"Chen","year":"2015","journal-title":"Oncogene"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.06.019","article-title":"Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients","volume":"83","author":"Heestand","year":"2017","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114024119","article-title":"Recurrent mutations in topoisomerase II\u03b1 cause a previously undescribed mutator phenotype in human cancers","volume":"119","author":"Boot","year":"2022","journal-title":"PNAS"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34631","article-title":"Targeted sequencing of cancer-related genes reveals a recurrent TOP2A variant which affects DNA binding and coincides with global transcriptional changes in glioblastoma","volume":"153","author":"Gielniewski","year":"2023","journal-title":"Int J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.06.061","article-title":"MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha","volume":"463","author":"Hua","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.7150\/jca.64017","article-title":"TOP2A promotes proliferation and metastasis of hepatocellular carcinoma regulated by miR-144-3p","volume":"13","author":"Wang","year":"2022","journal-title":"J Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e929120-1","DOI":"10.12659\/MSM.929120","article-title":"Expression of the topoisomerase II alpha (TOP2A) gene in lung adenocarcinoma cells and the association with patient outcomes","volume":"26","author":"Du","year":"2020","journal-title":"Med Sci Monit: Int Med J Exp Clin Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.2012069","article-title":"Type IIA topoisomerase (TOP2A) triggers epithelial-mesenchymal transition and facilitates HCC progression by regulating Snail expression","volume":"12","author":"Dong","year":"2026","journal-title":"Bioengineered"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/381602","article-title":"TOP2A amplification and overexpression in hepatocellular carcinoma tissues","volume":"2015","author":"Panvichian","year":"2015","journal-title":"BioMed Res Int"},{"key":"B15","article-title":"TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib","volume":"12","author":"Wang","year":"2022","journal-title":"Am J Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s42003-024-05939-7","article-title":"Macroscopic inhibition of DNA damage repair pathways by targeting AP-2\u03b1 with LEI110 eradicates hepatocellular carcinoma","volume":"7","author":"Wang","year":"2024","journal-title":"Commun Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12536","article-title":"Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the WHSC1\u2010mediated TOP2A\/PI3K\/AKT axis","volume":"38","author":"Bao","year":"2022","journal-title":"Kaohsiung J Med Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316408","article-title":"Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial","volume":"68","author":"Pinyol","year":"2019","journal-title":"Gut"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/database\/bar026","article-title":"International Cancer Genome Consortium Data Portal\u2014a one-stop shop for cancer genomics data","volume":"2011","author":"Zhang","year":"2011","journal-title":"Database: J Biol Database Curation"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5396128","article-title":"A new inflammation-related risk model for predicting hepatocellular carcinoma prognosis","volume":"2022","author":"Xing","year":"2022","journal-title":"BioMed Res Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","article-title":"UALCAN: An update to the integrated cancer data analysis platform","volume":"25","author":"Chandrashekar","year":"2022","journal-title":"Neoplasia (New York NY)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia (New York NY)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1311","article-title":"LncMAP: Pan-cancer atlas of long noncoding RNA-mediated transcriptional network perturbations","volume":"46","author":"Li","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad987","article-title":"The UCSC Genome Browser database: 2024 update","volume":"52","author":"Raney","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad1059","article-title":"JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles","volume":"52","author":"Rauluseviciute","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1055","article-title":"The Gene Ontology Resource: 20 years and still GOing strong","volume":"47","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa970","article-title":"KEGG: integrating viruses and cellular organisms","volume":"49","author":"Kanehisa","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3715","article-title":"Toward understanding the origin and evolution of cellular organisms","volume":"28","author":"Kanehisa","year":"2019","journal-title":"Protein Sci: A Publ Protein Soc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"PNAS"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics: A J Integr Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-157","article-title":"DKK1 promotes hepatocellular carcinoma cell migration and invasion through \u03b2-catenin\/MMP7 signaling pathway","volume":"12","author":"Chen","year":"2013","journal-title":"Mol Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3892\/mmr.2024.13415","article-title":"Advances in research on Malignant tumors and targeted agents for TOP2A (Review)","volume":"31","author":"Zhou","year":"2024","journal-title":"Mol Med Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2009.002","article-title":"Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment","volume":"153","author":"Bouchalova","year":"2009","journal-title":"Biomed Papers Med Faculty Univ Palacky Olomouc CzechoSlovakia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.4694","article-title":"Prediction of recurrence from metabolites and expression of TOP2A and EZH2 in prostate cancer patients treated with radiotherapy","volume":"36","author":"Hansen","year":"2023","journal-title":"NMR BioMed"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172716","article-title":"DNA topoisomerase II inhibition potentiates osimertinib\u2019s therapeutic efficacy in EGFR-mutant non\u2013small cell lung cancer models","volume":"134","author":"Chen","year":"2026","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/tox.23498","article-title":"circ_0089153 exacerbates breast cancer cells proliferation and metastasis via sponging miR-2467-3p\/E2F6","volume":"37","author":"Gao","year":"2022","journal-title":"Environ Toxicol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.69495","article-title":"A positive feedback loop of CENPU\/E2F6\/E2F1 facilitates proliferation and metastasis via ubiquitination of E2F6 in hepatocellular carcinoma","volume":"18","author":"Liu","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16240","article-title":"Unveiling the role of UPF3B in hepatocellular carcinoma: Potential therapeutic target","volume":"115","author":"Hou","year":"2024","journal-title":"Cancer Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12885-023-11703-7","article-title":"A hsa_circ_001726 axis regulated by E2F6 contributes to metastasis of hepatocellular carcinoma","volume":"24","author":"Ai","year":"2024","journal-title":"BMC Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208303","article-title":"The Wnt antagonist DICKKOPF-1 gene is a downstream target of \u03b2-catenin\/TCF and is downregulated in human colon cancer","volume":"24","author":"Gonz\u00e1lez-Sancho","year":"2005","journal-title":"Oncogene"},{"key":"B48","doi-asserted-by":"publisher","first-page":"596","DOI":"10.18632\/oncotarget.194","article-title":"The class I Hdac inhibitor Mgcd0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling","volume":"1","author":"Sikandar","year":"2010","journal-title":"Oncotarget"},{"key":"B49","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/cncr.27788","article-title":"High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery","volume":"119","author":"Shi","year":"2013","journal-title":"Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3369","article-title":"Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas","volume":"67","author":"Yamabuki","year":"2007","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603579","article-title":"The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types","volume":"96","author":"Forget","year":"2007","journal-title":"Br J Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00262-024-03655-z","article-title":"PGRN inhibits CD8+T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAM","volume":"73","author":"Zhou","year":"2024","journal-title":"Cancer Immunol Immunother: Cii"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.605619","article-title":"Tumor-derived myeloid cell chemoattractants and T cell exclusion in pancreatic cancer","volume":"11","author":"Vonderheide","year":"2020","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328364","article-title":"Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma","volume":"72","author":"Xiong","year":"2023","journal-title":"Gut"},{"key":"B55","doi-asserted-by":"publisher","first-page":"37117","DOI":"10.1038\/s41598-025-21123-1","article-title":"Programmed cell death-related genes define distinct molecular subtypes and risk profiles in hepatocellular carcinoma","volume":"15","author":"Yang","year":"2025","journal-title":"Sci Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1038\/s41598-025-89614-9","article-title":"BRD4 interacting genes as prognostic biomarkers in hepatocellular carcinoma for optimized treatment strategies","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210343","article-title":"Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition | Oncogene","volume":"26","author":"Han","year":"2007","journal-title":"Oncogene"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1109019","article-title":"Metabolomic analysis of vascular cognitive impairment due to hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2023","journal-title":"Front Neurol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-2025-546","article-title":"Investigation of mitochondrial DNA methylation-related prognostic biomarkers in hepatocellular carcinoma using The Cancer Genome Atlas (TCGA) database","volume":"14","author":"Shi","year":"2025","journal-title":"Trans Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.900380","article-title":"Machine learning screens potential drugs targeting a prognostic gene signature associated with proliferation in hepatocellular carcinoma","volume":"13","author":"Liu","year":"2022","journal-title":"Front Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809952\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:36:07Z","timestamp":1782970567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809952\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2026.1809952"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1809952","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1809952"}}